A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod

Journal of Infectious Diseases

Volumn 178, Issue 2, 1998, Pages 551-555

  Tyring, Stephen K ^a   Arany, Istvan ^b   Stanley, Margaret A ^b   Tomai, Mark A ^b   Miller, Richard L ^b   Smith, Michael H ^b   McDermott, Daniel J ^b   Slade, Herbert B ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; GENE PRODUCT; IMIQUIMOD; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VERRUCA VULGARIS; VIRUS GENE; WART VIRUS;

EID: 0031853904     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517472     Document Type: Article

References (14)

1. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10:122-63.
2. Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clin Infect Dis 1995; 20(suppl):S91-7.
3. Rudlinger R, Smith I, Bunney M, Hunter J. Human papillomavims infections in a group of renal transplant patients. Br J Derm 1986; 115:681-92.
4. Coleman N, Birley HDL, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994; 102:768-74.
5. Arany I, Tyring SK. Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions. Sex Transm Dis 1996; 23:475-80.
6. Arany I, Tyring SK. Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions. J Interferon Cytokine Res 1996; 16:453-60.
7. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134: 25-30.
8. Tomai MA, Birmachu W, Case MT, et al. Imiquimod: in vivo and in vitro characteristics and toxicology. In: Aly R, Beutner KR, Maibach H, eds. Cutaneous infection and therapy. New York, Marcel Dekker: 1997: 405-15.
9. Harrison CJ, Jenski L, Voychehovski T, Bernstein DI. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection [erratum appears in Antiviral Res 1989; 11:215]. Antiviral Res 1988; 10:209-23.
10. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 1992; 52:3528-33.
11. Arany I, Rady P, Tyring SK. Interferon treatment enhances the expression of underphosphorylated (biologically active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGF beta 1/IFN beta cytokine pathway. Antiviral Res 1994; 23:131-41.
12. Bishop PE, McMillan A, Fletcher S. An immunohistological study of spontaneous regression of condylomata acuminata. Genitourin Med 1990; 66:79-81.
13. Schonfeld A, Nitke S, Schattner A, et al. Intramuscular human interferon-beta injections in treatment of condylomata acuminata. Lancet 1984; 1: 1038-42.
14. Reis LF, Ho Lee T, Vilcek J. Tumor necrosis factor acts synergistically with autocrine interferon-beta and increases interferon-beta mRNA levels in human fibroblasts. J Biol Chem 1989;264:16351-4.